Searching for a common mechanism for placenta-mediated pregnancy complications and cardiovascular disease: role of lipoprotein(a) Ilaria Romagnuolo, M.Sc., Elena Sticchi, M.Sc., Ph.D., Monica Attanasio, M.Sc., Elisa Grifoni, M.D., Gabriele Cioni, M.D., Ph.D., Anna Paola Cellai, M.Sc., Rosanna Abbate, M.D., Cinzia Fatini, M.D., Ph.D. Fertility and Sterility Volume 105, Issue 5, Pages 1287-1293.e3 (May 2016) DOI: 10.1016/j.fertnstert.2016.01.014 Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Figure 1 Lipoprotein (a) [Lp(a)] levels according to each placenta-mediated pregnancy complications (PMPC). CNTRL = control; PE = preeclampsia; SB = stillbirth; SGA = small-for-gestational-age neonates. Fertility and Sterility 2016 105, 1287-1293.e3DOI: (10.1016/j.fertnstert.2016.01.014) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Figure 2 Lipoprotein (a) [Lp(a)] lconcentrations according to LPA gene unfavorable alleles burden. Fertility and Sterility 2016 105, 1287-1293.e3DOI: (10.1016/j.fertnstert.2016.01.014) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Supplemental Figure 1 Flow chart. PE = preeclampsia; SB = stillbirth; SGA = small-for-gestational-age neonates. Fertility and Sterility 2016 105, 1287-1293.e3DOI: (10.1016/j.fertnstert.2016.01.014) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions